uniQure N.V. (NASDAQ:QURE) issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.83) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.78) by $0.05, MarketWatch Earnings reports. uniQure N.V. had a negative return on equity of 135.97% and a negative net margin of 203.99%. The company had revenue of $4.94 million for the quarter, compared to the consensus estimate of $2.92 million.
uniQure N.V. (NASDAQ QURE) traded down 3.78% during midday trading on Friday, hitting $8.41. 35,910 shares of the stock were exchanged. The company’s market capitalization is $214.96 million. The company’s 50 day moving average is $7.71 and its 200 day moving average is $6.20. uniQure N.V. has a 1-year low of $4.72 and a 1-year high of $9.15.
COPYRIGHT VIOLATION NOTICE: This report was first published by Rincon Hill News and is the property of of Rincon Hill News. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://rinconhillneighbors.org/2017/08/19/uniqure-n-v-nasdaqqure-releases-earnings-results-misses-estimates-by-0-05-eps-updated.html.
In other news, insider Harald Petry sold 58,075 shares of the stock in a transaction dated Monday, June 26th. The stock was sold at an average price of $6.01, for a total value of $349,030.75. Following the transaction, the insider now directly owns 155 shares of the company’s stock, valued at $931.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 173,460 shares of company stock worth $1,042,986 over the last three months. Corporate insiders own 0.64% of the company’s stock.
QURE has been the subject of several recent research reports. Zacks Investment Research cut shares of uniQure N.V. from a “buy” rating to a “sell” rating in a report on Wednesday, May 17th. Oppenheimer Holdings, Inc. set a $17.00 target price on shares of uniQure N.V. and gave the stock a “buy” rating in a research note on Tuesday, May 16th. Cowen and Company restated a “buy” rating on shares of uniQure N.V. in a research note on Wednesday, May 24th. ValuEngine cut shares of uniQure N.V. from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, Chardan Capital set a $13.00 price target on shares of uniQure N.V. and gave the stock a “buy” rating in a research report on Sunday, July 23rd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company’s stock. uniQure N.V. currently has a consensus rating of “Hold” and a consensus price target of $15.04.
About uniQure N.V.
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with our FREE daily email newsletter.